Exenatide Once Monthly Showed Positive Results in Phase 2 Study

March 14, 2011

Press release from Eli Lilly

Amylin Pharmaceuticals, Eli Lilly and Company Alkermes, Inc., announce positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

The 121-patient, phase 2 study assessed the efficacy, safety and tolerability of three different doses of exenatide once monthly.

Article information
Topic:
Pharmaceutical industry
Author:
Source:
Eli Lilly
Added:
March 14, 2011
Free HCP newsletter
Join the newsletter
Free weekly news
Latest diabetes healthcare news direct to your inbox.
Email:
Profession:
NHS employee:
Latest forum posts
The latest forum threads from the Ask a Question forum.
Healthcare Search